Biomea Makes Menin-Ful Progress With Novel Diabetes Agent

Bouncing back from an FDA clinical hold in June, Biomea Fusion’s menin inhibitor has shown some early promise in a Phase II study in type 2 diabetes. The company is setting its sights on correcting beta-cell deficient patients with the drug’s unique mechanism.